{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:15:42Z","timestamp":1790878542043,"version":"4.1.0"},"reference-count":20,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.271604","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:35:17Z","timestamp":1776364517000},"page":"1425-1430","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical and First-in-Human Study of Carbonic Anhydrase IX\u2013Targeting Theranostic Pair, [\n                    <sup>68<\/sup>\n                    Ga]Ga\/[\n                    <sup>177<\/sup>\n                    Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma"],"prefix":"10.2967","volume":"67","author":[{"given":"Jingnan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026091707501238000_67.9.1425.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00359-2"},{"key":"2026091707501238000_67.9.1425.2","first-page":"39","article-title":"Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma","volume":"7","author":"Serzan","year":"2021","journal-title":"J Cancer Metastasis Treat."},{"key":"2026091707501238000_67.9.1425.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601333"},{"key":"2026091707501238000_67.9.1425.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"2026091707501238000_67.9.1425.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2026091707501238000_67.9.1425.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2026091707501238000_67.9.1425.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2026091707501238000_67.9.1425.8","doi-asserted-by":"crossref","first-page":"102881","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"2026091707501238000_67.9.1425.9","first-page":"802","article-title":"Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy","volume":"9","author":"Bui","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2026091707501238000_67.9.1425.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.024"},{"key":"2026091707501238000_67.9.1425.11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur Urol."},{"key":"2026091707501238000_67.9.1425.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170514"},{"key":"2026091707501238000_67.9.1425.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266309"},{"key":"2026091707501238000_67.9.1425.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267175"},{"key":"2026091707501238000_67.9.1425.15","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00259-024-07007-y","article-title":"Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial","volume":"52","author":"Yang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501238000_67.9.1425.16","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","article-title":"Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501238000_67.9.1425.17","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1007\/s00259-024-06801-y","article-title":"Diagnostic efficacy of [68Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma","volume":"51","author":"Zhu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501238000_67.9.1425.18","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1158\/1538-7445.AM2024-6024","article-title":"A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors [abstract]","volume":"84","author":"Mizukoshi","year":"2024","journal-title":"Cancer Res."},{"key":"2026091707501238000_67.9.1425.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268509"},{"key":"2026091707501238000_67.9.1425.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270958"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:50:58Z","timestamp":1789656658000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.271604"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271604","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}